Introduction: Anti-VEGF therapy is repeatedly given for an extended period of time to patients when treated for age-related macular degeneration. While short-term effects of anti-VEGF agents on retinal pigment epithelial cells have been investigated, the effects of long-term and repeated treatment on these cells are scarce. In this study, we have investigated the effects of anti-VEGF treatment (bevacizumab and aflibercept) after long-term, repeated treatment on uptake, storage, and subcellular localization. Methods: Experiments were conducted in primary porcine retinal pigment epithelium (RPE) cells in first passage and in ARPE-19 cell line. Cells were treated with 250 µg/mL bevacizumab, aflibercept, or, as a non-VEGF inhibiting antibody, rituximab once a week for 1 day, 7 days, 4, and 12 weeks. Cell survival was evaluated with methyl thiazolyl tetrazolium assay. Uptake and localization of compounds were investigated with immunofluorescence microscopy. Selective intracellular proteins were stained with specific respective primary antibodies; actin cytoskeleton was stained with phalloidin. For quantitative analysis, intracellular signals were normalized to light intensity and exposure time. Intracellular association with lysosomes (Lamp2) and exosomes (CD63) was also quantified. In addition, subcellular fractions (nucleus, plasma, membrane, and cytoskeleton) were generated and analyzed in Western blot. Results: Weekly treatment up to 12 weeks displayed no toxic effects on RPE cells in any substance tested. Intracellular signal of bevacizumab and aflibercept was strongest after 1 day, decreased after 1 and 4 weeks but increased again after 12 weeks. The signal of intracellular bevacizumab was significantly stronger than of aflibercept. In addition, in primary RPE, aflibercept was significantly more associated with Lamp2, indicating degradation of aflibercept. At all time points, the respective therapeutics could be detected at the cytoskeleton. In primary RPE cells, co-localization with exosome marker CD63 showed a maximum after 1 day for bevacizumab and after 12 weeks for aflibercept. Actin-encapsulated therapeutics can be found at any time point tested. Conclusion: Both bevacizumab and aflibercept display a distinctive time-dependent uptake in the RPE cells and are stored in actin-covered accumulations for extended periods of time. When normalized and quantified, less aflibercept can be found in RPE cells, while more aflibercept is co-localized with Lamp2. Our data suggest that bevacizumab is differently processed by RPE cells than aflibercept.

1.
Schmidt-Erfurth
U
,
Chong
V
,
Loewenstein
A
,
Larsen
M
,
Souied
E
,
Schlingemann
R
, et al.
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
.
Br J Ophthalmol
.
2014 Sep
;
98
(
9
):
1144
67
. .
2.
Rofagha
S
,
Bhisitkul
RB
,
Boyer
DS
,
Sadda
SR
,
Zhang
K
.
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)
.
Ophthalmology
.
2013 Nov
;
120
(
11
):
2292
9
.
3.
Lois
N
,
McBain
V
,
Abdelkader
E
,
Scott
NW
,
Kumari
R
.
Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy
.
Retina
.
2013 Jan
;
33
(
1
):
13
22
. .
4.
Young
M
,
Chui
L
,
Fallah
N
,
Or
C
,
Merkur
AB
,
Kirker
AW
, et al.
Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration
.
Retina
.
2014 Jul
;
34
(
7
):
1308
15
. .
5.
Gerding
H
.
Long-term results of intravitreal anti-VEGF injections in wet AMD: a meta-analysis
.
Klin Monbl Augenheilkd
.
2016 Apr
;
233
(
4
):
471
4
. .
6.
Klettner
A
,
Möhle
F
,
Roider
J
.
Intracellular bevacizumab reduces phagocytotic uptake in RPE cells
.
Graefes Arch Clin Exp Ophthalmol
.
2010 Jun
;
248
(
6
):
819
24
. .
7.
Klettner
A
,
Tahmaz
N
,
Dithmer
M
,
Richert
E
,
Roider
J
.
Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis
.
Br J Ophthalmol
.
2014 Oct
;
98
(
10
):
1448
52
. .
8.
Aboul Naga
SH
,
Dithmer
M
,
Chitadze
G
,
Kabelitz
D
,
Lucius
R
,
Roider
J
, et al.
Intracellular pathways following uptake of bevacizumab in RPE cells
.
Exp Eye Res
.
2015 Feb
;
131
:
29
41
. .
9.
Dithmer
M
,
Hattermann
K
,
Pomarius
P
,
Aboul Naga
SH
,
Meyer
T
,
Mentlein
R
, et al.
The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium
.
Exp Eye Res
.
2016 Apr
;
145
:
187
205
. .
10.
Ranjbar
M
,
Brinkmann
MP
,
Zapf
D
,
Miura
Y
,
Rudolf
M
,
Grisanti
S
.
Fc receptor inhibition reduces susceptibility to oxidative stress in human RPE cells treated with bevacizumab, but not aflibercept
.
Cell Physiol Biochem
.
2016
;
38
(
2
):
737
47
. .
11.
Vo
TA
,
Abedi
S
,
Schneider
K
,
Chwa
M
,
Kenney
MC
.
Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria
.
Exp Eye Res
.
2018 Dec
;
177
:
112
6
. .
12.
Spitzer
MS
,
Wallenfels-Thilo
B
,
Sierra
A
,
Yoeruek
E
,
Peters
S
,
Henke-Fahle
S
, et al.
Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells
.
Br J Ophthalmol
.
2006 Oct
;
90
(
10
):
1316
21
. .
13.
Klettner
AK
,
Kruse
ML
,
Meyer
T
,
Wesch
D
,
Kabelitz
D
,
Roider
J
.
Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells
.
Graefes Arch Clin Exp Ophthalmol
.
2009 Dec
;
247
(
12
):
1601
8
. .
14.
Schottler
J
,
Randoll
N
,
Lucius
R
,
Caliebe
A
,
Roider
J
,
Klettner
A
.
Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium
.
Exp Eye Res
.
2018 Jun
;
171
:
1
11
. .
15.
Wiencke
AK
,
Kiilgaard
JF
,
Nicolini
J
,
Bundgaard
M
,
Röpke
C
,
La Cour
M
.
Growth of cultured porcine retinal pigment epithelial cells
.
Acta Ophthalmol Scand
.
2003 Apr
;
81
(
2
):
170
6
. .
16.
Klettner
A
,
Roider
J
.
Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways
.
Invest Ophthalmol Vis Sci
.
2008 Oct
;
49
(
10
):
4523
7
. .
17.
Dunn
KC
,
Aotaki-Keen
AE
,
Putkey
FR
,
Hjelmeland
LM
.
ARPE-19, a human retinal pigment epithelial cell line with differentiated properties
.
Exp Eye Res
.
1996 Feb
;
62
(
2
):
155
69
. .
18.
Riss
TL
,
Moravec
RA
,
Niles
AL
,
Duellman
S
,
Benink
HA
,
Worzella
TJ
, et al.
Cell viability assays
. In:
Sittampalam
GS
,
Grossman
A
,
Brimacombe
K
,
Arkin
M
,
Auld
D
,
Austin
C
, et al.
, editors.
Assay guidance manual
.
Bethesda, MD
:
Eli Lilly & Company and the National Center for Advancing Translational Sciences
;
2004
.
19.
Hillenkamp
J
,
Dydykina
S
,
Klettner
A
,
Treumer
F
,
Vasold
R
,
Bäumler
W
, et al.
Safety testing of indocyanine green with different surgical light sources and the protective effect of optical filters
.
Retina
.
2010 Nov–Dec
;
30
(
10
):
1685
91
. .
20.
Middleton
S
.
Porcine ophthalmology
.
Vet Clin North Am Food Anim Pract
.
2010 Nov
;
26
(
3
):
557
72
. .
21.
Klettner
A
.
Retinal pigment rpithelium cell culture
. In:
Klettner
A
,
Dithmar
S
, editors.
Retinal pigment epithelium in health and disease
.
Switzerland
:
Springer Nature
;
2020
. p.
295
306
.
22.
Malik
D
,
Tarek
M
,
Caceres del Carpio
J
,
Ramirez
C
,
Boyer
D
,
Kenney
MC
, et al.
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
.
Br J Ophthalmol
.
2014 Jun
;
98
(
Suppl 1
):
i11
16
. .
23.
Sobolewska
B
,
Heiduschka
P
,
Bartz-Schmidt
KU
,
Ziemssen
F
.
pH of anti-VEGF agents in the human vitreous: low impact of very different formulations
.
Int J Retina Vitreous
.
2017
;
3
:
22
. .
24.
Klettner
A
,
Recber
M
,
Roider
J
.
Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture
.
Graefes Arch Clin Exp Ophthalmol
.
2014 Oct
;
252
(
10
):
1593
8
. .
25.
Dithmer
M
,
Fuchs
S
,
Shi
Y
,
Schmidt
H
,
Richert
E
,
Roider
J
, et al.
Fucoidan reduces secretion and expression of vascular endothelial growth factor in the retinal pigment epithelium and reduces angiogenesis in vitro
.
PloS One
.
2014
;
9
(
2
):
e89150
. .
26.
Geisen
P
,
McColm
JR
,
King
BM
,
Hartnett
ME
.
Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture
.
Curr Eye Res
.
2006 Sep
;
31
(
9
):
739
48
. .
27.
van Bilsen
K
,
van Hagen
PM
,
Bastiaans
J
,
van Meurs
JC
,
Missotten
T
,
Kuijpers
RW
, et al.
The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha
.
Br J Ophthalmol
.
2011 Jun
;
95
(
6
):
864
8
. .
28.
Klettner
A
,
Puls
S
,
Treumer
F
,
Roider
J
,
Hillenkamp
J
.
Compatibility of recombinant tissue plasminogen activator and bevacizumab co-applied for neovascular age-related macular degeneration with submacular hemorrhage
.
Arch Ophthalmol
.
2012 Jul
;
130
(
7
):
875
81
. .
29.
Klettner
A
,
Grotelüschen
S
,
Treumer
F
,
Roider
J
,
Hillenkamp
J
.
Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage
.
Br J Ophthalmol
.
2015 Jun
;
99
(
6
):
864
9
. .
30.
Simister
NE
,
Jacobowitz Israel
E
,
Ahouse
JC
,
Story
CM
.
New functions of the MHC class I-related Fc receptor, FcRn
.
Biochem Soc Trans
.
1997 May
;
25
(
2
):
481
6
. .
31.
Cohen
SY
,
Creuzot-Garcher
C
,
Darmon
J
,
Desmettre
T
,
Korobelnik
JF
,
Levrat
F
, et al.
Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration
.
Br J Ophthalmol
.
2007 Sep
;
91
(
9
):
1173
6
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.